Online citations, reference lists, and bibliographies.
← Back to Search

Carboplatin In Malignant Mesothelioma: A Phase II Study Of The Cancer And Leukemia Group B

N. Vogelzang, M. Goutsou, J. Corson, Y. Suzuki, S. Graziano, J. Aisner, M. Cooper, Kristine Coughlin, M. Green
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
SummaryCarboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (≤2,000 cells/μl) and thrombocytopenia (<100,000 cells/μl) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25%±7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.
This paper references
10.1007/BF00273404
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma
E. Mbidde (2004)
10.1001/ARCHSURG.1983.01390060092027
Cancer: Principles and Practice of Oncology
G. Steele (1983)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1200/JCO.1989.7.11.1748
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A. Calvert (1989)
10.1001/ARCHINTE.1987.00370120081015
Malignant mesothelioma with occupational and environmental asbestos exposure in an Illinois community hospital.
K. Wolf (1987)
10.1016/0277-5379(87)90125-8
High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study.
M. Gore (1987)
10.1200/JCO.1990.8.1.151
Phase II trial of carboplatin in the management of malignant mesothelioma.
D. Raghavan (1990)
10.1200/JCO.1989.7.5.651
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
T. Shea (1989)
10.2307/2531294
Confidence limits for probability of response in multistage phase II clinical trials.
Atkinson En (1985)
Non-random deletions of chromosome 3 (P14-21) in human malignant mesothelioma
NC Popescu (1987)
10.5555/URI:PII:0093775481900439
Chemotherapy in the treatment of malignant mesothelioma.
J. Aisner (1981)
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
M. Egorin (1984)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
10.1007/BF00273405
A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma
B. Cantwell (2004)
Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential.
S. Hsu (1988)
Confidence limits for probability of response in multistage phase II clinical trials.
E. Atkinson (1985)
Comparative activity of three platinum analogues against human malignant mesothelioma (HMM) xenografts in nude mice
AP Chahinian (1985)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1002/1097-0142(19840201)53:3<377::AID-CNCR2820530302>3.0.CO;2-B
Malignant mesothelioma. The university of minnesota experience
N. Vogelzang (1984)
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
D. Mintzer (1985)
Cisplatin with adriamycin or mitomycin for malignant mesothelioma: A randomized phase II trial
AP Chahinian (1987)
Response of mesothelioma to large doses of methotrexate with CF rescue (HDMTX-CF) used alone or with cis-platinum
I Djerassi (1985)



This paper is referenced by
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1634/theoncologist.2016-0121
Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
X. Wang (2017)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1016/S0039-6109(02)00033-6
Malignant mesothelioma: options for management.
S. Singhal (2002)
10.1177/1078155210373525
Vinflunine: review of a new vinca alkaloid and its potential role in oncology
J. S. Ng (2011)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1016/J.CRITREVONC.2003.10.001
Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments.
A. Catalano (2004)
10.3816/CLC.2003.N.023
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
Treating Malignant Pleural Mesothelioma : an update on the situation at the dawn of 2014
(2019)
10.1053/SONC.2002.30231
Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.
P. Baas (2002)
10.1053/j.seminoncol.2008.01.008
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
J. Bellmunt (2008)
10.1517/14728214.12.1.127
Emerging drugs for mesothelioma
G. Scagliotti (2007)
10.1007/s12094-013-1015-3
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens
E. Habib (2013)
10.1007/3-540-27329-8_9
Chemotherapie des malignen Pleuramesothelioms
S. Tomek (2005)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1093/ANNONC/MDF663
Pleura mesothelioma: combined modality treatments.
T. Cerny (2002)
10.1007/978-3-319-53560-9_15
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
M. Zauderer (2017)
10.1016/J.LUNGCAN.2004.04.020
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
S. Tomek (2004)
10.1007/0-387-28274-2_39
First-Line Chemotherapy for Malignant Pleural Mesothelioma
P. Jänne (2005)
10.1093/ANNONC/MDF664
The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.
G. Jerusalem (2002)
Liječenje malignog mezotelioma poplućnice
S. Cvitanović (2009)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1007/s00063-002-1181-5
Prognose, Staging und Therapie des malignen Pleuramesothelioms
W. Neumeister (2002)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1016/J.LUNGCAN.2006.09.011
Malignant pleural mesothelioma: a new standard of care.
R. Stahel (2006)
10.1097/00001622-200303000-00006
Chemotherapy for malignant pleural mesothelioma
S. Tomek (2003)
10.1016/J.HOC.2005.09.010
An overview of chemotherapy for mesothelioma.
L. Krug (2005)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
10.1158/1078-0432.CCR-06-9015
The Cancer and Leukemia Group B Respiratory Committee
E. Vokes (2006)
10.1378/CHEST.126.4.1318
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
M. Pistolesi (2004)
10.3816/CLC.2009.n.014
Malignant pleural mesothelioma: medical treatment update.
D. Vorobiof (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar